Semler Scientific (OTCMKTS:SMLR) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Semler Scientific (OTCMKTS:SMLRGet Rating) issued its quarterly earnings results on Monday. The medical equipment provider reported $0.41 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.48 by ($0.07), MarketWatch Earnings reports. Semler Scientific had a net margin of 32.48% and a return on equity of 44.76%.

OTCMKTS SMLR opened at $47.34 on Tuesday. The stock’s 50 day moving average is $50.02 and its two-hundred day moving average is $79.62. The company has a market capitalization of $320.02 million, a price-to-earnings ratio of 20.26 and a beta of 0.90. Semler Scientific has a 1-year low of $41.53 and a 1-year high of $153.21.

In other Semler Scientific news, CEO Douglas Murphy-Chutorian sold 2,000 shares of Semler Scientific stock in a transaction that occurred on Monday, February 28th. The stock was sold at an average price of $72.65, for a total transaction of $145,300.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 13.20% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in Semler Scientific in the 4th quarter worth $5,795,000. Wells Fargo & Company MN bought a new stake in Semler Scientific during the 4th quarter worth about $52,000. Goldman Sachs Group Inc. lifted its position in Semler Scientific by 0.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 151,955 shares of the medical equipment provider’s stock worth $13,927,000 after buying an additional 1,199 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Semler Scientific by 206.7% in the 4th quarter. The Manufacturers Life Insurance Company now owns 61,335 shares of the medical equipment provider’s stock valued at $5,621,000 after purchasing an additional 41,335 shares during the period. Finally, NEXT Financial Group Inc bought a new stake in shares of Semler Scientific in the 4th quarter valued at about $195,000. 44.69% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have recently issued reports on the company. Colliers Securities reaffirmed a “buy” rating on shares of Semler Scientific in a research report on Tuesday, March 22nd. Zacks Investment Research raised Semler Scientific from a “strong sell” rating to a “hold” rating in a research report on Thursday, March 24th. B. Riley decreased their target price on Semler Scientific from $145.00 to $70.00 and set a “buy” rating on the stock in a research report on Monday, March 7th. TheStreet downgraded Semler Scientific from a “b-” rating to a “c” rating in a report on Thursday, March 3rd. Finally, Lake Street Capital decreased their price objective on Semler Scientific from $175.00 to $100.00 in a report on Tuesday, March 1st. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $120.25.

Semler Scientific Company Profile (Get Rating)

Semler Scientific, Inc provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.

Recommended Stories

Earnings History for Semler Scientific (OTCMKTS:SMLR)

Receive News & Ratings for Semler Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Semler Scientific and related companies with MarketBeat.com's FREE daily email newsletter.